1. Tumor Size-driven Dose of Intraoperative Radiotherapy for Breast Cancer: 18 Gy Versus 21 Gy
- Author
-
F. Cavagnetto, Piero Fregatti, Stefano Agostinelli, Marina Guenzi, Daniele Friedman, Renzo Corvò, Elisabetta Bonzano, Monica Bevegni, and Liliana Belgioia
- Subjects
Cancer Research ,Intraoperative radiation therapy ,Tumor size ,business.industry ,medicine.medical_treatment ,Dose, Early-stage breast cancer, Intraoperative radiation therapy, Oncology, Cancer Research ,Significant difference ,General Medicine ,medicine.disease ,Early-stage breast cancer ,Breast cancer ,Oncology ,Dose ,Toxicity ,medicine ,Overall survival ,Nuclear medicine ,business ,Intraoperative radiotherapy ,Early breast cancer - Abstract
AIM To test whether a reduced total single dose of 18 Gy of intraoperative radiotherapy with electrons (IORT) may be tailored to safely treat patients in comparison with the standard dose of 21 Gy. (NCT01276938). PATIENTS AND METHODS From October 2009 to December 2011, 199 females affected by breast cancer were treated with conservative surgery and IORT with two different exclusive doses, 18 or 21 Gy. RESULTS The median follow-up was 91 months (16-104 months). Sixty-five patients (pT1a\b, pN0\mic, pMx, G1-G3) received 18 Gy and 134 patients (pT1c\2, pN0\mic, pMx, G1-G3) received 21 Gy. No significant difference in local recurrence-free survival or overall survival was detected in the 18 Gy-treated arm versus that treated with 21 Gy: 96.9% vs. 96.3%, p=0.72, and 96.9% vs. 95.5%, p=0.82, respectively at 5 years. CONCLUSION The lower dose of 18 Gy achieved excellent results in terms of local toxicity and local control in early breast cancer.
- Published
- 2018
- Full Text
- View/download PDF